Interleukin (IL)-33 may play a role in rheumatoid arthritis (RA) pathophysiology as shown by human studies and murine models \[[@CR1]\]. Previously, we demonstrated that detectable serum IL-33 predicts clinical response to rituximab independently of auto-antibody status \[[@CR2]\].

Here, we aimed to investigate whether the prediction of therapeutic response using serum IL-33 level is generalizable to all biologic agents, including TNF inhibitors (TNFi) and non-TNFi in RA.

We set up an ancillary study of the ROC (Rotation or Change of Biotherapy After First Anti-TNF Treatment Failure for RA) trial (NCT01000441) which compared the efficacy of TNFi vs non-TNFi in patients with insufficient response to a first TNFi \[[@CR3]\]. Three hundred patients were randomized, and treatment efficacy was evaluated at 24 weeks according to EULAR response, showing that a non-TNFi was more effective in achieving EULAR response than a TNFi. Serum IL-33 level was assessed before treatment using an accurate enzyme-linked immunosorbent assay (ELISA IL-33, Quantikine, R&D Systems) \[[@CR4]\]. Statistical analyses used Prism (Mann-Whitney and Fisher tests for quantitative and qualitative values, respectively). Serum IL-33 level was defined as detectable when \> 6.25 pg/mL (lower threshold).

Results were analyzed for 267 patients with available serum and clinical data (Table [1](#Tab1){ref-type="table"}). Serum IL-33 level was detectable for 109/267 (40.8%) patients (mean ± standard deviation serum level was 49.7 ± 61.0 pg/mL when detectable) (Table [2](#Tab2){ref-type="table"}). IL-33 detection was associated with auto-antibody positivity: rheumatoid factor (RF) and/or anti-cyclic citrullinated peptide antibody (anti-CCP), either combined or analyzed separately (Table [3](#Tab3){ref-type="table"}). Auto-antibody positivity was not associated with response to the different treatment: TNFi (*N* = 132, odds ratio (OR) = 1.1, 95% confidence interval (CI) = 0.39--3.16), non-TNFi (*N* = 130, OR = 1.5, 95% CI = 0.40--5.62), or different sub-groups of non-TNFi (data not shown). There was no association between IL-33 detection and response to TNFi as well as to non-TNFi drugs overall or analyzed separately (Table [2](#Tab2){ref-type="table"}). Likewise, there was no difference when comparing the levels of serum IL-33 between responders and non-responders in TNFi and non-TNFi groups (data not shown).Table 1Characteristics of the patients included in the ancillary study of the ROC trialCharacteristicsTNFiNon-TNFi biologicTotalNumber of women (%)114 (85.7)110 (82.1)224 (83.9)Mean age (SD)55.9 (13.0)58.4 (11.2)57.2 (12.1)Number rheumatoid factor-positive (%)108 (82.4)101 (76.5)209 (79.8)Number anti-CCP-positive (%)102 (79.7)105 (82.7)207 (81.2)Mean DAS28-CRP (SD)4.7 (0.9)4.8 (1.1)4.8 (1.0)Table 2EULAR response, IL-33 detectability rates and association between IL-33 detection and response to tumor necrosis factor inhibitor (TNFi; including adalimumab, certolizumab, etanercept and infliximab) and non-TNFi (including abatacept, rituximab, and tocilizumab) in patients from the ROC studyTreatmentNumber of patientsNumber of EULAR responders (%)Number of detectable IL-33 among all patients (%)Number of detectable IL-33 among EULAR responders (%)Association between IL-33 detectability and EULAR response (OR \[95% CI\])TNFiAdalimumab5330 (56.6)23 (43.4)14 (46.7)1.4 \[0.5--4.1\]Etanercept4929 (59.2)20 (40.8)13 (44.8)1.5 \[0.5--5.0\]Certolizumab2310 (43.5)10 (43.5)5 (50.0)1.6 \[0.3--8.5\]Infliximab81 (12.5)3 (37.5)1 (100)6.6 \[0.2--226\]Total TNFi13370 (52.6)56 (42.1)33 (47.1)1.6 \[0.8--3.1\]Non-TNFiRituximab3720 (54.0)10 (27.0)6 (30.0)1.4 \[0.3--6.1\]Abatacept3018 (60.0)11 (36.6)8 (44.4)2.4 \[0.5--11.9\]Tocilizumab6753 (79.1)32 (47.8)25 (47.2)0.9 \[0.3--2.9\]Total non-TNFi13491 (67.9)53 (39.6)39 (42.9)1.6 \[0.7--3.3\]Results are presented as odds ratios (OR) \[95% confidence intervals (CI)\]Table 3Association between IL-33 detection and auto-antibody positivityAuto-antibody statusNumber of patientsOR95% CIRF+ and/or anti-CCP+ vs RF− and anti-CCP−26221.12.8-158.3RF+ vs RF−2639.73.7-25.3Anti-CCP+ vs anti-CCP−2552.71.3- 5.7Results are presented as odds ratios (OR), 95% confidence intervals (CI) for each factor*RF* rheumatoid factor, *Anti-CCP* anti-cyclic citrullinated peptide antibody

Thus, this new study confirms the association between serum IL-33 detection and seropositivity in RA patients. However, it did not replicate the association between IL-33 detection and response to rituximab. This may be due to a lack of power related to the number of patients who received this treatment (*N* = 37), but it may also reflect the difficulty of studying IL-33 as a possible predictor of response given its association with seropositivity, which is a well-known factor associated with response to some biologics such as rituximab or abatacept \[[@CR5]\].

In conclusion, we confirm that serum IL-33 detection is associated with auto-antibody positivity but is not a predictive marker for response to TNFi and non-TNFi in RA.
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